Claims for Patent: 10,537,635

Summary for Patent: 10,537,635

Title:	Detection of arginine methylation of EGFR for prediction of resistance to therapy
Abstract:	This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
Inventor(s):	Hung; Mien-Chie (Houston, TX), Liao; Hsin-Wei (Houston, TX), Hsu; Jung-Mao (Houston, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	15/036,797
Patent Claims:	1. A method of treating a patient having cancer comprising administering an effective amount of cetuximab to a patient in need thereof, said patient having been determined to have a cancer cell comprising (i) unmethylated Arg at position 198 and/or (ii) unmethylated Arg at position 200 of a EGFR protein expressed in the cancer cell. 2. The method of claim 1, further comprising administering a second anticancer therapy. 3. The method of claim 2, wherein the second anticancer therapy is a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, toxin therapy, immunotherapy, or cytokine therapy. 4. The method of claim 1, wherein the cancer is colorectal, breast, prostate, lung, or pancreatic cancer. 5. The method of claim 1, wherein the cancer cell is from a biopsy sample. 6. The method of claim 1, wherein the cancer cell is a circulating tumor cell. 7. The method of claim 1, wherein the presence of (i) unmethylated Arg at position 198 and (ii) unmethylated Arg at position 200 of EGFR protein is detected by mass spectrometry, ELISA, flow cytometry, immunohistochemistry, western blot, radioimmunoassay, or immunoprecipitation. 8. The method of claim 1, wherein the presence of (i) unmethylated Arg at position 198 and (ii) unmethylated Arg at position 200 of EGFR protein is detecting by a method comprising contacting the sample with an antibody that binds specifically to EGFR methylated at Arg198 and Arg200.

Details for Patent 10,537,635

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-11-19
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-11-19